China grants conditional approval for Merck's COVID-19 drug
BEIJING, Dec. 30 (Xinhua) -- China has activated special approval procedures and granted conditional approval for the import registration of Merck's COVID-19 treatment Molnupiravir, the National Medical Products Administration said Friday.
Molnupiravir, developed by Merck & Co., Inc., is a small-molecule oral drug for adult patients with mild to moderate COVID-19 symptoms and a high risk of progressing to severe cases, according to the administration.
It can be given to patients who, for instance, are elderly, overweight, or have chronic renal diseases, diabetes, severe cardiovascular diseases, and chronic lung diseases.
The administration asked the drug's marketing authorization holder to continue relevant research, fulfill conditional requirements within the specified time, and submit follow-up research results promptly.
Photos
Related Stories
- Chinese premier congratulates new Nepali PM on inauguration
- Philippine president to visit China
- Pakistani, Chinese staff join hands to make CPEC success story: minister
- Chinese experts answer public's questions about COVID-19 prevention
- New Omicron subvariant accounts for over 40 pct of new COVID-19 cases in U.S.
Copyright © 2022 People's Daily Online. All Rights Reserved.